<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845140</url>
  </required_header>
  <id_info>
    <org_study_id>MS200661_0003</org_study_id>
    <nct_id>NCT03845140</nct_id>
  </id_info>
  <brief_title>L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children</brief_title>
  <official_title>An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of L-praziquantel orodispersible (L-PZQ ODT)
      tablets in Schistosoma infected children aged 3 months to 6 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Participants With Clinical Cure</measure>
    <time_frame>17 to 21 days post-treatment</time_frame>
    <description>Clinical cure is defined as no parasite eggs in the stool or urine 17 to 21 days post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Reduction Rate</measure>
    <time_frame>Pre-treatment, 17 to 21 days post-treatment</time_frame>
    <description>Egg reduction rate will be calculated using parasite egg counts as determined by the Kato Katz method for Cohorts 1, 2 and 3 and the urine filtration method for Cohort 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>17 to 21 days post-treatment</time_frame>
    <description>Cure defined as no evidence of parasite antigens in urine as measured with Point-of-Care Circulating Cathodic Antigen (POC-CCA) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the Study Intervention</measure>
    <time_frame>Day 1</time_frame>
    <description>Acceptability of the study intervention will be recorded as the reaction of participants to study intervention. The acceptability will be assessed by the nurse/site staff for all children enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment Related Adverse Events</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
    <description>Number of participants with clinically significant changes will be reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">311</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Treatment 1a: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 4 to 6 years infected with Schistosoma (S.) mansoni will receive single oral dose of L-PZQ ODT 50 milligram/Kilogram (mg/Kg) after food-intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Treatment 1b: Biltricide®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 4 to 6 years infected with S. mansoni will receive single oral dose of Biltricide® 40 mg/Kg crushed tablet after food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 to 3 years infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 to less than 24 months infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 months to 6 years infected with S. haematobium will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake. Additional participants will receive 60 mg/Kg of L-PZQ ODT as decided by the Independent data monitoring committee (IDMC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-PZQ ODT</intervention_name>
    <description>Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.</description>
    <arm_group_label>Cohort 1, Treatment 1a: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 2: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 3: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biltricide®</intervention_name>
    <description>Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.</description>
    <arm_group_label>Cohort 1, Treatment 1b: Biltricide®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-PZQ ODT</intervention_name>
    <description>Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.</description>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of the participant is 4 to 6 years of age (Cohorts 1 and 4), 2 to 3 years of age
             (Cohorts 2 and 4) 3 to less than 24 months of age (Cohorts 3 and 4)

          -  Participants are; Schistosoma (S.) mansoni positive (Cohorts 1, 2, and 3); diagnosis
             defined as positive egg counts in stool greater than or equal to ( &gt;=) 1 egg per 1
             occasion) according to World Health Organization (WHO) classification [1]: light (1 to
             99 eggs per gram of feces), moderate (100 to 399 eggs per gram of feces) and heavy (&gt;=
             400 eggs per gram of feces) infections; S. haematobium positive (Cohort 4); diagnosis
             defined as positive egg counts in urine (&gt;= 1 egg per 10 milliliter(mL) urine)
             according to WHO classification (Prevention and Control of Schistosomiasis and Soil
             Transmitted Helminthiasis. WHO Technical Report Series No. 912. WHO, Geneva,
             Switzerland, 2002).light (less than (&lt;) 50 eggs per 10 mL of urine) and heavy (&gt;=50
             eggs per 10 mL of urine) infections

          -  Participants have a minimum body weight of 8.0 Kilograms (Kg) in 2 to 6 years of age
             children and 5.0 Kg in 3 months to &lt; 24 months of age infants and toddlers

          -  Parent's or guardian/legally authorized representative's ability to communicate well
             with the Investigator and his/her delegate, to understand the protocol requirements
             and restrictions, and to be willing to have their children comply with the
             requirements of the entire study, that is:

               -  To be examined by a study physician at screening and 17 to 21 days after
                  treatment

               -  To provide stool samples at screening and 17 to 21 days after treatment

               -  To provide urine samples at screening and 17 to 21 days after treatment

               -  To provide venous blood samples for laboratory assessments

               -  To be housed in the clinic for 12 to 24 hours

               -  To provide venous blood samples for pharmacokinetics (PK) assessments (for
                  participants in the PK subset)

          -  Participants have a minimum hemoglobin level of 10 gram per deciliter

        Exclusion Criteria:

          -  Participants with following medical conditions are excluded from the study; Findings
             in the clinical examination and/or laboratory safety examination on the treatment day,
             that in the opinion of the Investigator constitute a risk or a contraindication for
             the child's participation in the study or that could interfere with the study
             objectives, conduct or evaluation. This includes but is not restricted to bacterial or
             viral infections, such as dysentery, gastroenteritis, ascites, jaundice, etc.;
             Participants with seizures and/or medical history of seizures and/or other signs of
             potential central nervous system involvement; Participants with known cysticercosis,
             or with signs or symptoms (for example: subcutaneous nodules) suggestive of
             cysticercosis; Participants with an acute infection or other acute illness within the
             7 days prior to study screening; Debilitating illness such as tuberculosis,
             malnutrition, etc.

          -  Treatment with PZQ within the 4 weeks prior to the study screening

          -  Concomitant treatment (within 2 weeks prior to enrollment) with medication that might
             affect the metabolism of PZQ, such as certain anti epileptics (for example:
             carbamazepine or phenytoin), glucocorticosteroids (for example: dexamethasone),
             chloroquine, rifampicin or cimetidine (see Biltricide® Summary of Product
             Characteristics [SmPC])

          -  Treatment within the 2 weeks prior to the study screening with anti malarial
             medications

          -  For infants and toddlers being breast fed, treatment of the mothers/wet nurses with
             PZQ in the 3 days prior to PZQ ODT administration

          -  Participation in any clinical study within 4 weeks prior to administration of PZQ ODT,
             or anticipated at any time until completion of the End of study visit

          -  Participants with marked increases of the liver enzymes: alanine aminotransferase
             and/or aspartate aminotransferase above 3 times the upper limit of normal (ULN); total
             bilirubin level above 1.5 times the ULN

          -  Participants with hepatosplenic schistosomiasis

          -  Fever, defined as temperature above 37.5 degree Celsius axillary or oral mixed S.
             haematobium and S. mansoni infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitè de Cocody</name>
      <address>
        <city>Abidjan</city>
        <zip>22BP770</zip>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>eliezerngoran@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Eliezer N'Goran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kemri Kisumu</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>pmwinzi@kemri.org</email>
    </contact>
    <investigator>
      <last_name>Pauline Mwinzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
    <country>Kenya</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200661_0003</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schistosomiasis</keyword>
  <keyword>Children</keyword>
  <keyword>L-praziquantel</keyword>
  <keyword>Biltricide®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Merck KGaA, Darmstadt, Germany is committed to sharing patient-level data and supporting documentation from applicable studies according to company policies. Further information on data sharing and how to request data can be found on our website: https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

